Coya Therapeutics sees success in early COYA-302 FTD trial, aims for Phase 2b in H2 2025 and ALS filing in Q2 2025. Read why ...

Coya Therapeutics (COYA) announced interim results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and ...

Dr. Arun Swaminathan, Coya’s Chief Executive Officer followed: “The results thus far are consistent with previously published encouraging data from an open-label investigator-initiated study ...

Coya Therapeutics, Inc.’s COYA share price has surged by 6.94%, which has investors questioning if this is right time to sell ...

Shares of COYA stock opened at $6.53 on Tuesday. Coya Therapeutics has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The stock’s fifty day moving average is $6.18 and its ...

Coya Therapeutics (COYA) announced publication of the results of a study designed to evaluate the effects of COYA 303, Coya’s investigational ...

Learn all the tips and tricks of COYA’s famous drinks and ceviches at this masterclass… Looking for a fun cooking class in ...

It’s a fun one for things to do in Dubai this weekend… There are lots of fun things to do in Dubai this weekend. From ...

Results from the first patient cohort (N=5) of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in ...

Coya Therapeutics, Inc. (COYA) closed the last trading session at $6.64, gaining 1.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...